IDH1 and astrocytoma (excluding glioblastoma): Based on the preclinical evidence, a phase 1 trial of IDH1 peptide vaccine in IDH1-mutant and 1p19q-intact grade III-IV astrocytomas has been completed [89] (ClinicalTrials.gov NCT02454634).